Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.The early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced stages require adjuvant interdictions such as radiotherapy and chemotherapy. Platinum and anthracycline drugs have long been used as standard adjuvant chemotherapy drugs for advanced and recurrent endometrial carcinomas. In one study, the standard combination adjuvant treatment with AP was found to be more effective as an adjuvant therapy than whole abdominal irradiation

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Endometrial Carcinoma Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

20 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Sohag university Hospital

Sohag, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• Age group: Histologically diagnosed with primary endometrial carcinoma

more than 20 years old.

Any histological type of endometrial carcinoma
Stage III, IV
Stage one I or II with one or more of the following factors:

Histologic grade 3 endometroid carcinoma with myometrial invasion still within half of the myometrium
histological grade 1,2 endometroid carcinomas with invasion of over half of myometrium
cervical stromal invasion
vascular invasion; or
serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma
performance status 0-2
adequate function of all major organs

Exclusion criteria

• Pt has received prior radiation or chemotherapy.

Pt with sarcomatous component
Metastatic endometrial carcinoma
Other malignancy
Unfit patient for chemotherapy

Treatment and study plan

Paclitaxel/epirubcin/carboplatin

Drug

adjuvant treatment in endometrial carcinoma

Paclitaxel/Carboplatin

Drug

Dose dense paclitaxel/carboplatin

Primary outcomes

Completion rate of chemotherapy

Time frame: 6 months

6 cycles

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Oct 26, 2023
Registry last updated: May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed